| 郭军,刘登湘,王娜,等.阿帕替尼对卵巢癌术后复发铂类耐药的影响[J].安徽医药,2022,26(3):603-606. |
| 阿帕替尼对卵巢癌术后复发铂类耐药的影响 |
| Effect of apatinib on platinum resistance in patients with ovarian cancer after recurrence |
| |
| DOI：10.3969/j.issn.1009-6469.2022.03.043 |
| 中文关键词: 卵巢肿瘤 阿帕替尼 抗药性，肿瘤 复发 铂类耐药 |
| 英文关键词: Ovarian neoplasms Apatinib Drug resistance, neoplasm Relapse Platinum resistance |
| 基金项目:河北省医学科学研究重点课题计划( 20181617) |
|
| 摘要点击次数: 1120 |
| 全文下载次数: 321 |
| 中文摘要: |
| 目的探讨阿帕替尼治疗卵巢癌术后复发铂类耐药的临床价值。方法选择 2017年 10月至 2019年 3月期间邢台市人民医院 66例卵巢癌术后复发铂类耐药的病人作为研究对象，采用随机数字表法分为阿帕替尼联合化疗组、化疗组及阿帕替尼单药组，各 22例。其中联合化疗组给予阿帕替尼 +多西他赛(或吉西他滨)治疗， 4个周期后阿帕替尼单药维持；化疗组给予多西他赛(或吉西他滨)治疗；单药组给予单独阿帕替尼治疗。 4周为 1个周期，本研究开始服药即开始随访。比较三组病人的疗效，并比较无进展生存期( PFS)、客观缓解率( ORR)、疾病控制率( DCR)、总生存期( OS)以及不良反应发生率。结果三组病人 ORR及 DCR比较差异有统计学意义(P<0.05)；两两比较:联合化疗组 ORR及 DCR均高于化疗组与单药组( P<0.05)；单药组 DCR高于化疗组( P<0.05)；单药组 ORR与化疗组比较差异无统计学意义( P>0.05)。联合化疗组中位 PFS为 8.8(7.9~9.6)个月，化疗组中位 PFS为 5.9(5.1~6.8)个月，单药组中位 PFS为 7.1(6.7~7.6)个月，联合化疗组疾病进展风险显著低于化疗组及单药组( P<0.05)单药组疾病进展风险显著低于化疗组( P<0.05)。联合化疗组中位 OS为 9.0(8.6~9.3)个月，化疗组中位 OS为 |
| 英文摘要: |
| Objective To explore the clinical value of apatinib in the treatment of postoperative recurrence of ovarian cancer with platinum resistance.Methods From October 2017 to March 2019, 66 patients with platinum-resistant ovarian cancer after surgery inXingtai People′s Hospital were selected as the research subjects, and they were divided into apatinib combined chemotherapy group,chemotherapy group and apatinib single-agent group with 22 cases in each group, by the random number table method. Among them,the combined chemotherapy group was given apatinib + docetaxel (or gemcitabine) treatment and apatinib single-agent maintenance after 4 cycles; the chemotherapy group was given docetaxel (or gemcitabine) treatment; and the single-agent group was given apatinib alone. Every 4 weeks is a cycle, and the follow-up starts immediately after taking the drug in this study. The efficacy of the three groups of patients was compared, and the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), overallsurvival (OS), and incidence of adverse reactions were compared.Results There were significant differences in ORR and DCR among the three groups (P<0.05); pairwise comparison: ORR and DCR in the combined chemotherapy group were higher than those in the chemotherapy group and the single-agent group (P<0.05); the DCR of the single-agent group was higher than of the chemotherapy group (P <0.05); there was no significant difference in ORR between the single-agent group and the chemotherapy group (P>0.05). The median PFS of the combined chemotherapy group was 8.8 (7.9-9.6) months, the median PFS of the chemotherapy group was 5.9 (5.1-6.8) months, and the median PFS of the single-agent group was 7.1 (6.7-7.6) months. The risk of disease progression in the combined chemotherapy group was significantly lower than that in the chemotherapy group and the single-agent group (P<0.05), and the risk of disease progression in the single-agent group was significantly lower than that in the chemotherapy group (P<0.05). The median OS of the combined chemotherapy group was 9.0 (8.6-9.3) months, the median OS of the chemotherapy group was 6.0 (4.3-7.6) months, and the median OS of the single-agent group was 7.0 (6.2-7.7) months. The risk of disease death in the combined chemotherapy group was significantly lower than that in the chemotherapy group and the single-agent group (P<0.05), and the risk of disease death in the single-agent group was significantly lower than that in the chemotherapy group (P<0.05). There was no significant difference in the total incidence of adverse reactions among the three groups (P>0.05).Conclusion Apatinib combined with chemotherapy significantly improves theORR and DCR, prolongs the survival time, does not increase the degree of adverse reactions and can be tolerated by patients, which hasimportant clinical significance for the postoperative recurrence of ovarian cancer with platinum resistance therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
